Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Tablet Scoring Final Guidance Requires Generics To Be Same As Brand

Executive Summary

Generic industry concerns that scoring conventions could create barriers to entry did not win out in final tablet scoring guidance; FDA says to contact it if the scoring convention is patent protected.

You may also be interested in...



Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data

US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.

Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data

US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.

FDA Will Allow ANDA Corrections … Until 10 Minor Deficiencies Found

GDUFA refuse-to-receive draft guidance says that agency will allow sponsors to make a few small fixes to their applications, but FDA won’t accept any ANDAs that have big problems.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel